注射PRP与透明质酸治疗膝骨关节炎的研究  

Research on Injection of PRP and Hyaluronic Aacid in the Treatment of Knee Osteoarthritis

作　　者：侯威[1] 张卫[1] 周淑平[1] Hou Wei;Zhang Wei;Zhou Shuping(Nanhua Hospital Affiliated to Nanhua University,Hengyang,421000)

机构地区：[1]南华大学附属南华医院

出　　处：《基因组学与应用生物学》2019年第12期5676-5683,共8页Genomics and Applied Biology

摘　　要：通过对膝关节骨性关节炎(OA)患者临床试验,研究关节内注射血小板的血浆PRP和透明质酸HA对膝关节OA患者的临床结果和生活质量的长期影响。该非安慰剂对照的随机临床试验包括160例受膝关节OA影响的患者、1~4级的凯尔格伦-劳伦斯量表。在PRP组(n=87)中,在4周间隔内进行2次关节内注射,HA组(n=73)在1周间隔内进行了3次关节内注射。问卷调查之后,对所有患者在治疗前和治疗后12个月进行了前瞻性评估。使用SPSS 16.1软件对结果进行分析。在12个月的随访中,两组WOMAC疼痛评分和身体疼痛均有显著改善;然而,与HA组相比,PRP组的结果较好(p<0.001)。其他WOMAC和SF-36参数仅在PRP组中得到改善。两组患者2级OA患者均得到更多改善。本研究表明PRP注射液比HA注射液在减少症状和改善生活质量方面更有效,是选择对常规治疗没有反应的膝关节OA患者的治疗方案。This research was aim to study the long-term effects of platelet-injected plasma(PRP) and hyaluronic acid(HA) on the clinical outcome and quality of life in knee OA patients through clinical trials of osteoarthritis of the knee. The placebo-controlled randomized clinical trial consisted of 160 patients who were affected by knee OA, 1~4 level Kellgren-Lawrence scale. In the PRP group(n=87), 2 intra-articular injections were performed at a 4 week interval, and the HA group(n=73) carried out 1 intra-articular injections in the 3 week interval. After the arthritis index(WOMAC) and SF-36 questionnaires, all patients were prospectively assessed for 12 months before and after treatment. The results were analyzed using SPSS 16.1 software. During the 12 month follow-up, both groups showed significant improvement in WOMAC pain score and physical pain, however, the results of PRP group were better than those of HA group(p<0.001). Other WOMAC and SF-36 parameters are only improved in the PRP group. Both groups of patients with level 2 OA were more improved. This study showed that PRP injection was more effective than HA injection in reducing symptom and improving quality of life, and it is the choice for the treatment of OA patients who do not respond to routine treatment.

关 键 词：膝关节骨关节炎 关节内注射 血小板丰富血浆 透明质酸 

分 类 号：R684.3[医药卫生—骨科学]